The World Health Organisation (WHO) has sought information from the Government of India regarding the Rajasthan maternal deaths case linked to oxytocin injections manufactured by Jackson Laboratories, even as the Centre clarified that the request is part of a routine global pharmacovigilance process and should not be interpreted as a finding against either the company or its product.
Meanwhile, the Union government has cancelled the manufacturing licences of Jackson Laboratories’ units in Punjab and Himachal Pradesh after joint inspections by the Central Drugs Standard Control Organisation (CDSCO) and state drug regulators found deficiencies in compliance with Good Manufacturing Practices (GMP).
Officials said investigations into the maternal deaths and the quality of the medicines supplied are ongoing, while the Centre has also sought a detailed report from the Rajasthan government before deciding on any further action.
Regulatory Action Intensifies
According to Union Health Ministry officials, WHO routinely seeks information from national regulators to assess whether reported incidents are isolated or could have implications for other countries where a medicine may have been distributed.
They stressed that the organisation’s communication is a standard international safety surveillance measure rather than evidence of wrongdoing. Following inspections of Jackson Laboratories’ facilities, the respective state licensing authorities revoked the company’s manufacturing licences based on deficiencies identified by the joint inspection teams.
Officials described the move as part of the government’s “zero-tolerance” approach towards violations of pharmaceutical quality and manufacturing standards, adding that further regulatory action will depend on the findings of the ongoing investigation.
Questions Over Drug Safety
The regulatory action follows reports linking oxytocin injections manufactured by Jackson Laboratories to maternal deaths and severe kidney complications among women who underwent Caesarean deliveries at government hospitals in Rajasthan.
Earlier investigations had raised concerns over the quality of the supplied injections, prompting scrutiny of manufacturing practices as well as the wider drug supply chain. The Centre has maintained that all aspects of the case, including medicine quality, regulatory compliance and the sequence of events leading to the deaths, remain under investigation, while authorities await the Rajasthan government’s detailed report to establish the facts.
Investigation Continues Across States
The Centre has said that regulatory authorities will continue examining manufacturing records, quality control procedures and supply chain documentation as part of the ongoing investigation. Officials have maintained that the cancellation of the manufacturing licences is a precautionary regulatory measure based on inspection findings and does not, by itself, establish that the oxytocin injections caused the maternal deaths.
They added that the final conclusions will depend on laboratory analysis, forensic evidence and the outcome of the investigations being conducted by both central and state authorities.
The Logical Indian’s Perspective
The loss of mothers during childbirth is a tragedy that demands both accountability and sensitivity. While regulatory agencies must act swiftly against any lapse in drug quality or manufacturing standards, investigations must also remain evidence-based and transparent to maintain public trust.
Strong pharmacovigilance systems, rigorous inspections and timely communication between health authorities are essential to safeguarding patients and preventing similar incidents. As the inquiry continues, how can India strengthen its drug safety ecosystem to ensure that every patient receives medicines that meet the highest standards of quality and care?
